RCS - Ondine Biomedical - Hospital to adopt Steriwave as standard-of-care

Ondine BiomedicalAnnouncement

09/10/2023 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231009:nRSI0532Pa&default-theme=true

RNS Number : 0532P  Ondine Biomedical Inc.  09 October 2023

9 October 2023

ONDINE BIOMEDICAL INC.

 

("Ondine Biomedical", "Ondine" or the "Company")

 

Hospital to adopt Steriwave as standard-of-care

Penticton Regional Hospital (PRH), located in the Okanagan area of British
Columbia, has committed to implementing Canadian life sciences company Ondine
Biomedical's (LON: OBI) Steriwave® nasal photodisinfection technology as
standard-of-care for patients undergoing orthopedic surgery. Penticton
Regional Hospital, affiliated with UBC Faculty of Medicine, currently
undertakes approximately 900 orthopedic surgeries annually.

The PRH team has selected Steriwave as a highly effective method of preventing
hospital-acquired infections (HAIs) following surgery. This is particularly
important due to growing concern about antimicrobial resistance (AMR), as
hospitals must adapt their protocols to combat the rapid rise of
drug-resistant pathogens.

One in nine hospital patients in Canada gets a healthcare-associated infection
(HAI) resulting in around 12,000 deaths a year.(1) HAIs are also becoming
harder to treat due to rising rates of antimicrobial resistance (AMR) which
are making some commonly used antibiotics ineffective.(2) This has meant that
one in 19 deaths in Canada are now attributable to antibiotic-resistant
infections.(3) The cost of AMR to the Canadian healthcare sector is also
projected to increase from $1.4 billion to $7.6 billion per year by 2050.(4)

Ondine Biomedical's CEO, Carolyn Cross, said:

"We are very pleased that Steriwave will soon be adopted as the
standard-of-care for patients undergoing orthopedic surgeries performed at
Penticton Regional Hospital. It is gratifying to be working with Interior
Health and this orthopedics team who are so committed to combatting the risk
of post-surgical infections and keeping their patients safe against rising
rates of antibiotic resistance. This also demonstrates Steriwave's growing
status as an effective alternative to topical antibiotics for infection
prevention that easily fits into existing hospital workflows."

Ondine's nasal photodisinfection treatment kills all types of pathogens -
viruses, bacteria, and fungi - without causing resistance and is already in
use in major hospitals across Canada, including Vancouver General and UBC
Hospitals in BC, The Ottawa Hospital (Ontario), the Mazankowski Alberta Heart
Institute (Alberta), and the Montreal Heart Institute (Quebec).

Nasal photodisinfection is a non-antibiotic method for nasal decolonization
that uses a proprietary light-activated agent to destroy pathogens. First, the
agent is applied to each nostril using a nasal swab, then the area is
illuminated with a specific wavelength of light. The light activates the
photodynamic agent, causing an oxidative burst that destroys pathogens. In
this single, 5-minute treatment, Steriwave eliminates infection-causing
bacteria, viruses, and fungi in the nose.(5)

 

**ENDS**

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian headquartered company innovating in the
field of photodisinfection therapies. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection platform, in various
stages of development. Products beyond nasal photodisinfection include
therapies for a variety of medical indications such as chronic sinusitis,
ventilator-associated pneumonia, burns, and other indications.

About Nasal Photodisinfection

Ondine's nasal photodisinfection is a patented technology using a proprietary
photosensitizer (non- antibiotic, light-activated agent) to destroy pathogens.
The photodisinfection treatment is carried out by a trained healthcare
professional, and is an easy-to-use, painless, two-step process. The
photosensitizer is applied to each nostril using a nasal swab, followed by
illumination of the area with a specific wavelength of laser light for less
than five minutes. The light activates the photosensitizer, causing an
oxidative burst that is lethal to all types of pathogens. A key benefit of
this approach, unlike with antibiotics, is that pathogens do not develop
resistance to the therapy.

Nasal decolonization with antibiotics is already standard practice in many
hospitals prior to surgery, as pathogens in a patient's nasal cavities are a
major cause of surgical site infections (SSIs). However, there is a growing
need to reduce antibiotic use and find non-antibiotic methods of nasal
decolonization as resistance rates have been reported as high as 81%.(2)

Ondine's nasal photodisinfection system has a CE mark in Europe and the UK and
is approved in Canada and several other countries under the name Steriwave™.
It has been used in Canada for over ten years, with no serious adverse events
reported. In the US, it is currently undergoing clinical trials for regulatory
approval.

About Penticton General Hospital

The Penticton Regional Hospital (PRH) is in the Okanagan health service area
and responsible for providing core medical and surgical specialty services to
patients throughout its service area.  Located in Penticton, between Kelowna
and Oliver, PRH offers services including 24-hour emergency and trauma
services, acute services, ambulatory and outpatient clinics, and
diagnostic/paramedical services.

 1 
https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet
(https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet)

(2) Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015 Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub
2015 Jul 3.

(3) Healthcare-associated infections and antimicrobial resistance in Canadian
acute care hospitals, CCDR 49(5) - C anada.ca

(4) Healthcare-associated infections and antimicrobial resistance in Canadian
acute care hospitals, CCDR 49(5) - Canada.ca

(5) Liu Z, Norman G, Iheozor-Ejiofor Z, Wong JK, Crosbie EJ, Wilson P. Nasal
decontamination for the prevention of surgical site infection in
Staphylococcus aureus carriers. Cochrane Database Syst Rev. 2017 May
18;5(5):CD012462. doi: 10.1002/14651858.CD012462.pub2. PMID: 28516472; PMCID:
PMC6481881.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAFFFSIIRLTIIV